摘要
表皮生长因子受体酪氨酸激酶抑制剂(EGFRTKI),如吉非替尼和厄洛替尼改善非小细胞肺癌(NSCLC)患者的生存。不幸的是,获得性耐药终会出现在大多数最初对治疗有反应的患者中。目前已知的针对获得性耐药的分子机制,可能仅解释约70%的临床病例。在这项研究中,使用非小细胞肺癌细胞模型H1650,我们构建了一个吉非替尼耐药细胞株h1650gr在增加剂量和长期药物暴露实验。RNA测序和全基因组SNP阵列进行调查的转录组和基因组改变可能参与了吉非替尼耐药性。通过比较h1650gr和H1650细胞之间的表达谱,我们确定了许多的差异表达基因,其中包括FOXM1(DEGS)。在PI3K/Akt通路,预测Akt活性将被抑制。然而,基因在吉非替尼诱导的细胞凋亡中扮演着重要的角色,包括TP53、FOXO3和BAD,且没有上调。信号网络分析(IPA)典型相关通路分析显示,在h1650gr细胞下p53信号被抑制,下调促凋亡基因Fas、PUMA、Noxa,上调抗凋亡基因BIRC5 /存活素 。此外,大量的免疫相关基因差异表达,其中吉非替尼耐药中的作用需要进一步调查。利用全基因组拷贝数变化(CNAS)同样进行了分析而且Noxa位于h1650gr独特的拷贝数损失区,18q21。我们的研究结果表明,在h1650gr中高表达的EGFR-TKI耐药可能是由多方面因素综合产生的。
关键词: CNAS,差异表达基因,耐药性,EGFR激酶抑制剂,肺癌,SNV,转录组。
Current Cancer Drug Targets
Title:An Integrative Analysis of the Putative Gefitinib-resistance Related Genes in a Lung Cancer Cell Line Model System
Volume: 15 Issue: 5
Author(s): Xiaohong Han, Manjiao Liu, Shuai Wang, Guanting Lv, Li Ma, Changqing Zeng and Yuankai Shi
Affiliation:
关键词: CNAS,差异表达基因,耐药性,EGFR激酶抑制剂,肺癌,SNV,转录组。
摘要: The epidermal growth factor receptor-tyrosine kinase inhibitors (EGFRTKI), such as gefitinib and erlotinib have improved the survival of patients with nonsmall cell lung cancer (NSCLC). Unfortunately, acquired resistance will eventually develop in most patients who initially respond to the therapy. Currently known molecular mechanisms for such an acquired resistance may interpret only about 70% of clinical cases. In this study, using NSCLC cell model H1650, we constructed a gefitinib resistant cell line H1650GR through long term drug exposure with increased doses. RNA sequencing and whole genome SNP array were applied to investigate the transcriptome and genome alterations possibly involved in gefitinib resistance. By comparing the expression profiles between H1650GR and H1650 cells, we identified a large set of differentially expressed genes (DEGs), including FOXM1. In the PI3K/AKT pathway, AKT activity was predicted to be inhibited. However, genes that play important roles in gefitinib-induced apoptosis, including TP53, FOXO3 and BAD, were not up-regulated. Ingenuity Pathway Analysis (IPA) canonical pathway analysis showed that p53 signaling was inhibited in H1650GR cells, with down-regulation of pro-apoptosis genes FAS, PUMA, NOXA, and upregulation of anti-apoptosis genes BIRC5/Survivin. Besides, a large number of immune response-related genes were differently expressed, the role of which in gefitinib resistance requires further investigation. Whole genome copy number alterations (CNAs) were also analyzed and NOXA was located in the H1650GR unique copy number loss region, 18q21. Our results suggested that the much higher EGFR-TKI resistance in H1650GR may be produced by the integration of multi-aspect factors.
Export Options
About this article
Cite this article as:
Xiaohong Han, Manjiao Liu, Shuai Wang, Guanting Lv, Li Ma, Changqing Zeng and Yuankai Shi , An Integrative Analysis of the Putative Gefitinib-resistance Related Genes in a Lung Cancer Cell Line Model System, Current Cancer Drug Targets 2015; 15 (5) . https://dx.doi.org/10.2174/1568009615666150416122422
DOI https://dx.doi.org/10.2174/1568009615666150416122422 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Simple C-2-Substituted Quinolines and their Anticancer Activity
Letters in Drug Design & Discovery Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies
Current Medicinal Chemistry HLA-I Antigen Presentation and Tapasin Influence Immune Responses Against Malignant Brain Tumors-Considerations for Successful Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Prediction and Analysis of Hepatocellular Carcinoma Related Genes Using Gene Ontology and KEGG
Current Bioinformatics Hyaluronic Acid: The Reason for Its Variety of Physiological and Biochemical Functional Properties
Applied Clinical Research, Clinical Trials and Regulatory Affairs Mevalonate Kinase Deficiency: Disclosing the Role of Mevalonate Pathway Modulation in Inflammation
Current Pharmaceutical Design Nanotherapy Targeting the Tumor Microenvironment
Current Cancer Drug Targets Targeting Cytotoxic Conjugates of Somatostatin, Luteinizing Hormone- Releasing Hormone and Bombesin to Cancers Expressing Their Receptors: A “Smarter” Chemotherapy
Current Pharmaceutical Design Cancer Cell Permeability-Glycoprotein as a Target of MDR Reverters: Possible Role of Novel Dihydropyridine Derivatives
Current Drug Targets Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
Current Pharmaceutical Design Estrogen(s) and Analogs as a Non-Immunogenic Endogenous Ligand in Targeted Drug/DNA Delivery
Current Medicinal Chemistry Polymer-Drug Nanoconjugate – An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs
Pharmaceutical Nanotechnology Synthesis and Antitumor Evaluation of Thiophene Analogs of Kigelinone
Letters in Organic Chemistry Inhaled Micro/Nanoparticulate Anticancer Drug Formulations: An Emerging Targeted Drug Delivery Strategy for Lung Cancers
Current Cancer Drug Targets Expression and Function of Angiomodulating Cytokines in Rheumatoid Arthritis and Experimental Arthritis: Important Therapeutic Targets
Current Immunology Reviews (Discontinued) Bioactive Cyclohexenones: A Mini Review
Current Bioactive Compounds Molecular Pathways Linking Inflammation and Cancer
Current Molecular Medicine MBD1 is an Epigenetic Regulator of KEAP1 in Pancreatic Cancer
Current Molecular Medicine Systemic Delivery of siRNA: Challenging but Promising
Recent Patents on Drug Delivery & Formulation